Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)

Main Article Content

Elaine Siegfried
Lawrence Eichenfeld
Pearl Kwong
Seemal Desai
Susan Cutler
Cynthia Wilson
Pamela Rumney
Christine Crosby
Jennifer Andres
Mark McBride


VP-102, phase 3 trial, molluscum contagiosum, safety, efficacy




1. Ware O et.al. Racial Limitations of Fitzpatrick Skin Type. Cutis. 2020;105: 77-80.

2. Eichenfield L et.al. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device
Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum. Am J Clin Dermatol. 2021. Mar;22(2): 257-265.

Most read articles by the same author(s)

1 2 3 > >>